Value-Based Insurance Design and the COVID-19 Pandemic

- 68% of adults report out-of-pocket costs would be very or somewhat important in their decision to get care if they had symptoms of the coronavirus
- Patient out-of-pocket costs for COVID-19 hospitalization can reach:
  - $1,300 in employer sponsored health plans
  - $1,400-1,600 in traditional Medicare and Medicare Advantage plans
- 40% of Americans don’t have $400 for an unexpected bill

Value-based insurance design principles can mitigate the harmful effects of the virus by reducing barriers to necessary care

### Policies to Increase Access to Necessary Care

**March 11, 2020:** Notice 2020-15, HDHPs and Expenses Related to COVID-19, extended pre-deductible coverage for medical services to test for and treat the virus

**March 18, 2020:** Families First Coronavirus Response Act
- Eliminated cost-sharing for COVID-19 testing
- Eliminated cost-sharing for any in-person or telehealth provider visit that results in a COVID-19 test

**March 29, 2020:** Several private plans waive cost-sharing for COVID-19 treatment, in both privately insured individual and groups plans, and Medicare Advantage and Medicaid

**April 11, 2020:** CMS and the Departments of Labor and Treasury required health plans to cover COVID-19 diagnostic testing and certain related items and services provided during a medical visit without cost-sharing

**March 11, 2020:** Private health plans begin to announce partial or full coverage for COVID-19 testing and related services

**March 27, 2020:** Coronavirus Aid, Relief, and Economic Security Act (CARES)
- Mandates coverage of COVID-19 testing by all plans without cost-sharing
- Allows HSA-HDHPs to cover telehealth services - including care not associated with COVID-19 - on a pre-deductible basis
- Requires first dollar coverage of a COVID-19 vaccine in all plans by amending Public Health Service Act Section 2713

**March 30, 2020:** CMS expanded Medicare coverage of telehealth visits and issued regulatory changes to further support hospitals, physicians, and other healthcare organizations

**November 10, 2020:** CMS announced that Medicare beneficiaries can receive coverage of monoclonal antibodies to treat COVID-19 with no cost-sharing during the public health emergency

Policies that reduce consumer cost-sharing are mostly voluntary and need to be swiftly and generously implemented to encourage patients to seek necessary care